GoAI
Get started
Traws Pharma, Inc. logo

Traws Pharma, Inc.

TRAW

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.53

+$0.01 · +1.92%

Aug 21, 4:00 PM ET

TRAW company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

60

Fair Value

Momentum

17

Strong Down

Sentiment

53

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Iain D. Dukes
Listed since
Jul 25, 2013
Employees
7

Market position

Day range

Current $0.53

52-week range

Current $0.53

Open
$0.52
Previous close
$0.52
Volume
219.73K
0.09× average
Average volume
2.35M
Average daily volume
Market cap
8.07M USD
Beta
1.56
Market reference 1
50-day average
$0.6698
-20.87% below average
200-day average
$1.5051
-64.79% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.48M USD
P/E (TTM)
-0.61×
P/B (TTM)
-1.06×
P/S (TTM)
0×
EV / EBITDA
-0.31×
Earnings yield
98.63%
Free cash flow yield
-223.39%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-1457.87%
Return on assets
86.37%
Return on invested capital
3379.02%

Financial health

Debt / equity
0×
Current ratio
0.72×
Altman Z-score
-121.21
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2781%-7028%-16836%-26644%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 94.69%Gross margin, FY2025: 100.00%Operating margin, FY2021: -7299.12%Operating margin, FY2022: -8684.51%Operating margin, FY2023: -8981.42%Operating margin, FY2024: -21835.40%Operating margin, FY2025: -640.68%Net margin, FY2021: -7151.77%Net margin, FY2022: -8391.15%Net margin, FY2023: -8384.07%Net margin, FY2024: -24192.04%Net margin, FY2025: 328.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 94.69%. Gross margin FY2025 100.00%. Operating margin FY2021 -7299.12%. Operating margin FY2022 -8684.51%. Operating margin FY2023 -8981.42%. Operating margin FY2024 -21835.40%. Operating margin FY2025 -640.68%. Net margin FY2021 -7151.77%. Net margin FY2022 -8391.15%. Net margin FY2023 -8384.07%. Net margin FY2024 -24192.04%. Net margin FY2025 328.67%.

Income trends

Revenue

2.79M USD+1134.51%

Operating income

−17.88M USD+63.78%

Net income

9.17M USD+63.84M USD
Income trends across reported periods15.55M USD−9.98M USD−35.52M USD−61.06M USDRevenue, FY2021: 226K USDRevenue, FY2022: 226K USDRevenue, FY2023: 226K USDRevenue, FY2024: 226K USDRevenue, FY2025: 2.79M USDOperating income, FY2021: −16.5M USDOperating income, FY2022: −19.63M USDOperating income, FY2023: −20.3M USDOperating income, FY2024: −49.35M USDOperating income, FY2025: −17.88M USDNet income, FY2021: −16.16M USDNet income, FY2022: −18.96M USDNet income, FY2023: −18.95M USDNet income, FY2024: −54.67M USDNet income, FY2025: 9.17M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 226K USD. Revenue FY2022 226K USD. Revenue FY2023 226K USD. Revenue FY2024 226K USD. Revenue FY2025 2.79M USD. Operating income FY2021 −16.5M USD. Operating income FY2022 −19.63M USD. Operating income FY2023 −20.3M USD. Operating income FY2024 −49.35M USD. Operating income FY2025 −17.88M USD. Net income FY2021 −16.16M USD. Net income FY2022 −18.96M USD. Net income FY2023 −18.95M USD. Net income FY2024 −54.67M USD. Net income FY2025 9.17M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.79M USD226K USD226K USD226K USD226K USD
Cost of goods sold—12K USD———
Gross profit2.79M USD214K USD226K USD226K USD226K USD
Research and development12.14M USD130.31M USD11.43M USD11.41M USD7.3M USD
Selling, general, and administrative8.52M USD12.29M USD9.09M USD8.45M USD9.43M USD
Operating expenses20.67M USD49.56M USD20.52M USD19.85M USD16.72M USD
Depreciation and amortization61K USD12K USD16K USD14K USD14K USD
Operating income−17.88M USD−49.35M USD−20.3M USD−19.63M USD−16.5M USD
Net income9.17M USD−54.67M USD−18.95M USD−18.96M USD−16.16M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
70%
7 beats, 3 misses, 0 met estimates
Average EPS surprise
-282.33%
10 comparable reports
Latest EPS result
-0.16
Estimate -0.34 · Beat by 52.24%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.99-1.36-5.71-10.06Q2 '25BeatQ2 '25EstimateQ3 '25BeatQ4 '25BeatQ2 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported May 15, 2025: actual 2.09, estimate -8.04, surprise +126.00%, Beat. Q2 2025, reported May 21, 2025: actual —, estimate -8.75, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual -0.11, estimate -8.75, surprise +98.74%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.34, estimate -9.16, surprise +96.29%, Beat. Q2 2026, reported Apr 15, 2026: actual -0.82, estimate -1.91, surprise +57.07%, Beat. Q2 2026, reported May 15, 2026: actual -0.53, estimate -0.92, surprise +42.39%, Beat. Q3 2026, reported Aug 14, 2026: actual -0.16, estimate -0.335, surprise +52.24%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.95M1.98M1.01M47.6KQ3 '24MissQ4 '24MissQ1 '25MissQ2 '25MissQ2 '25EstimateQ3 '25BeatQ4 '25EstimateQ4 '26Estimate
Q3 2024, reported Aug 12, 2024: actual 57K USD, estimate 60K USD, surprise -5.00%, Miss. Q4 2024, reported Nov 15, 2024: actual 57K USD, estimate 60K USD, surprise -5.00%, Miss. Q1 2025, reported Mar 31, 2025: actual 56K USD, estimate 60K USD, surprise -6.67%, Miss. Q2 2025, reported May 15, 2025: actual 57K USD, estimate 60K USD, surprise -5.00%, Miss. Q2 2025, reported May 21, 2025: actual —, estimate 60K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 2.73M USD, estimate 60K USD, surprise +4455.00%, Beat. Q4 2025, reported Nov 13, 2025: actual —, estimate 60K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 12, 2026: actual —, estimate 2.71M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.00

88.68% upside
Past 12 months12-month forecastHigh $1.00Average $1.00Low $1.00

TRAW news

globenewswire.com

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical…

Read source
defenseworld.net

Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened

Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares were traded during…

Read source
globenewswire.com

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human…

Read source
benzinga.com

Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study

Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.

Read source
globenewswire.com

Traws Pharma Provides Regulatory Update on Influenza Program

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced…

Read source
globenewswire.com

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option…

Read source

Corporate actions

Corporate action history

Stock split

Effective Sep 23, 2024

1:25

Stock split

Effective May 21, 2021

1:15

Stock split

Effective Sep 26, 2018

1:15

Stock split

Effective Jun 1, 2016

1:10

TRAW peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TRAW

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
146.26
Weight
—
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
128.79
Weight
—
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research TRAW

research.disclaimer